The laboratory of Jeffrey L. Dage, PhD, is focused on the discovery and development of biomarkers to aid in the understanding of neurodegenerative diseases. Dr. Dage has more than 20 years of experience in drug discovery and early clinical development holding roles as an individual contributor, scientific group leader and management. He has successfully led research groups in diverse areas such as analytical chemistry, stem cell biology and translational science with broad impact across therapeutic areas.
Dr. Dage has continually been on the forefront of identification, development, and application of novel technologies that answer disease relevant biological questions encountered in the course of drug discovery and clinical development. Most recently he has led the discovery and development of phosphorylated tau as a novel blood biomarker for Alzheimer’s disease clinical trials. This blood test has proven to be useful for identification of Alzheimer’s disease pathology and risk of cognitive decline.
Dr. Dage is also the Scientific Director for the Biomarker Assay Laboratory in the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD).
